303 related articles for article (PubMed ID: 22003003)
21. Evidence-based medical therapy of patients with acute coronary syndromes.
Ramanath VS; Eagle KA
Am J Cardiovasc Drugs; 2007; 7(2):95-116. PubMed ID: 17503881
[TBL] [Abstract][Full Text] [Related]
22. Secondary medical prevention after primary vascular surgery between 1996 and 2006: a shift towards more evidence-based treatment.
Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
Eur J Prev Cardiol; 2013 Oct; 20(5):763-70. PubMed ID: 22637739
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological prevention of cardiovascular diseases].
Okovityĭ SV; Kulikov AN; Shulenin KS
Eksp Klin Farmakol; 2011; 74(11):43-7. PubMed ID: 22288160
[TBL] [Abstract][Full Text] [Related]
24. (8) Cardiovascular disease and risk management.
American Diabetes Association
Diabetes Care; 2015 Jan; 38 Suppl():S49-57. PubMed ID: 25537708
[No Abstract] [Full Text] [Related]
25. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?
Rabelink TJ
Nephrol Dial Transplant; 2004 Jan; 19(1):23-6. PubMed ID: 14671033
[No Abstract] [Full Text] [Related]
26. Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease.
Kitrou P; Katsanos K; Karnabatidis D; Reppas L; Brountzos E; Spiliopoulos S
Curr Vasc Pharmacol; 2017; 15(5):430-445. PubMed ID: 28595535
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
[No Abstract] [Full Text] [Related]
28. Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke.
Hackam DG; Kapral MK
Can J Neurol Sci; 2004 Aug; 31(3):295-303. PubMed ID: 15376471
[TBL] [Abstract][Full Text] [Related]
29. Personalized genomes and cardiovascular disease.
Musunuru K
Cold Spring Harb Perspect Med; 2014 Sep; 5(1):a014068. PubMed ID: 25256177
[TBL] [Abstract][Full Text] [Related]
30. Personalizing antiplatelet therapies: What have we learned from recent trials?
Landry S; Tanguay JF; Lordkipanidzé M
Platelets; 2018 Mar; 29(2):131-139. PubMed ID: 28628345
[TBL] [Abstract][Full Text] [Related]
31. Prevention of cardiovascular events in elderly people.
Andrawes WF; Bussy C; Belmin J
Drugs Aging; 2005; 22(10):859-76. PubMed ID: 16245959
[TBL] [Abstract][Full Text] [Related]
32. [Is there still an actual place for cardiovascular prevention in the elderly? Focus on antiplatelet and lipid lowering agents].
Radermecker RR; Lancellotti P
Rev Med Liege; 2014; 69(5-6):318-22. PubMed ID: 25065239
[TBL] [Abstract][Full Text] [Related]
33. Use of genetic data to guide therapy in arterial disease.
Ross S; Nejat S; Paré G
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S281-9. PubMed ID: 26149037
[TBL] [Abstract][Full Text] [Related]
34. [Direct oral anticoagulants in cardiology].
Kiss RG
Orv Hetil; 2016 Sep; 157(38):1507-10. PubMed ID: 27640616
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Cavallari LH; Mason DL
Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
[TBL] [Abstract][Full Text] [Related]
36. Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies.
Bryniarski L; Pelc-Nowicka A; Zabojszcz M; Mirek-Bryniarska E
Cardiol J; 2009; 16(2):179-89. PubMed ID: 19387970
[TBL] [Abstract][Full Text] [Related]
37. Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".
Paraskevas KI
J Vasc Surg; 2008 Sep; 48(3):776-7; author reply 777. PubMed ID: 18727983
[No Abstract] [Full Text] [Related]
38. Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.
Harada S; Zhou Y; Duncan S; Armstead AR; Coshatt GM; Dillon C; Brott BC; Willig J; Alsip JA; Hillegass WB; Limdi NA
Clin Pharmacol Ther; 2017 Sep; 102(3):493-501. PubMed ID: 28124392
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of lipid lowering, hypoglycemic, antihypertensive and antiplatelet medications on carotid artery intima-media thickness progression: a network meta-analysis.
Huang R; Mills K; Romero J; Li Y; Hu Z; Cao Y; Huang H; Xu Y; Jiang L
Cardiovasc Diabetol; 2019 Jan; 18(1):14. PubMed ID: 30700294
[TBL] [Abstract][Full Text] [Related]
40. Impact of partner bereavement on quality of cardiovascular disease management.
Shah SM; Carey IM; Harris T; Dewilde S; Victor CR; Cook DG
Circulation; 2013 Dec; 128(25):2745-53. PubMed ID: 24255060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
